Pet Diabetes Care Market Report 2025

The pet diabetes care market size has grown strongly in recent years. It will grow from $2.21 billion in 2024 to $2.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to growing awareness of pet health, advancements in veterinary medicine, prevalence of diabetes in pets, humanization of pets, increased focus on pet nutrition, awareness campaigns by veterinary organizations, availability of insulin and medications.

The pet diabetes care market size is expected to see strong growth in the next few years. It will grow to $3.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to rise in pet insurance adoption, customized diabetes management plans, focus on preventive pet healthcare, globalization of pet health trends, increasing investments in pet healthcare research, rising consumer affluence. Major trends in the forecast period include advancements in veterinary diagnostics, focus on pet obesity management, innovation in insulin delivery systems, rise in pet insurance coverage, increased availability of specialized pet foods:, telemedicine and remote monitoring, collaborations in veterinary medicine.

The pet diabetes care market is anticipated to grow due to a rise in pet adoption. Pet adoption refers to bringing animals from shelters or rescues into homes, which is becoming more common than purchasing pets from breeders or stores. The annual diagnosis of diabetes in pets is increasing, largely due to lifestyle similarities characterized by sedentary behavior and a diet high in processed foods. For instance, in 2022, Animal Medicines Australia, a non-governmental organization based in Australia, reported a notable increase in pet ownership, with the number of pet owners reaching 28,730.8 in 2022, compared to 39% in 2021. This represents a 24% rise, indicating a strong upward trend in pet adoption and investment in pet care. The increase in pet ownership underscores the growing popularity of pets in Australian households. Therefore, the rise in pet adoption is driving growth in the pet diabetes care market.

The increasing demand for pet insurance is expected to propel the growth of the pet diabetes care market in the future. Pet insurance provides financial protection that covers a portion of the veterinary expenses associated with pet care, helping pet owners manage the costs related to their pets' healthcare needs. This insurance typically covers the diagnosis, treatment, and management of diabetes, influenced by factors such as the pet's age, breed, and location. For example, in May 2023, the North American Pet Health Insurance Association (NAPHIA), a U.S.-based health insurance organization, reported that 5.36 million pets were insured in North America in 2022, reflecting a 21.7% increase from the 4.4 million insured in 2021. Consequently, the rising demand for pet insurance is contributing to the growth of the pet diabetes care market.

Increased research and development efforts, along with the introduction of new products, are key trends gaining traction in the pet diabetes market. Various studies are underway to better understand diabetes in animals and simplify its management. Additionally, companies are launching new offerings, such as generic drugs, to maintain their competitive edge in the market. In December 2022, the U.S. Food and Drug Administration (FDA), a scientific regulatory agency, approved a medication from Elanco Animal Health Inc. for cats suffering from a specific type of diabetes, marking it as the first oral medication authorized for this condition in animals.

Leading companies in the pet diabetes care market are concentrating on developing innovative technological products, such as the Petrackr diabetes monitoring device, to deliver reliable services to customers. The Petrackr diabetes monitoring device is a veterinary blood glucometer designed to monitor diabetes in cats and dogs. For instance, in May 2023, Universal Biosensors Inc., an Australia-based biosensor company, introduced the Petrackr diabetes monitoring device. This device provides blood glucose test results in just seconds and is user-friendly for both pet parents and veterinary clinicians. It is compatible with the Petrackr app, enabling users to easily record, monitor, and report their results.

In September 2022, Zoetis, a US-based animal health company, acquired Jurox for an undisclosed amount. With this acquisition, Zoetis aims to broaden the company's line of animal health products and provide opportunities to accelerate international growth by expanding its portfolio of animal parasiticides and anti-infectives. Jurox is an Australia-based veterinary pharmaceutical manufacturer that provides medicines for pets with diabetes.

Major companies operating in the pet diabetes care market are C.H. Boehringer Sohn AG & Co. KG, Becton Dickinson and Company, Merck & Co Inc., Zoetis Inc., Trividia Health Inc., Allison Medical Inc., UltiMed Inc., Apotex Inc., Henry Schein VET GmbH, Medtrust Holdings Inc., i-SENS Inc., Taidoc Technology Corp., Covetrus Inc., ALR Technologies Inc., Vet Innovations Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, AgaMatrix Inc., Ascensia Diabetes Care Holdings AG, Bayer AG, Dexcom Inc., LifeScan Inc., Medtronic PLC, Novo Nordisk A/S, Sanofi S.A., Senseonics Holdings Inc., Tandem Diabetes Care Inc., Terumo Corporation, Animas Corporation, Insulet Corporation, Roche Diabetes Care Inc.

North America was the largest region in the pet diabetes care market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pet diabetes care market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pet diabetes care market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pet diabetes care addresses diabetes in pets, a condition that can lead to additional health issues such as heart disease, pancreatitis, urinary tract infections, kidney disease, and skin infections. Diabetes in pets arises from insufficient insulin production, its complete absence, or improper utilization, hindering the conversion of food into energy within their bodies.

The primary drug types within pet diabetes care comprise insulin therapy and oral medication. Insulin therapy aims to elevate peripheral glucose intake while reducing hepatic glucose synthesis, thereby regulating blood glucose levels in pets. Devices utilized for pet diabetes care encompass glucose monitoring devices and insulin delivery systems. These care measures cater to various animals such as canines, felines, and other species, implemented across veterinary clinics, home care settings, and veterinary hospitals.

The pet diabetes care market research report is one of a series of new reports that provides pet diabetes care market statistics, including pet diabetes care industry global market size, regional shares, competitors with an pet diabetes care market share, detailed pet diabetes care market segments, market trends and opportunities, and any further data you may need to thrive in the pet diabetes care industry. This pet diabetes care market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pet diabetes care market includes revenues earned by entities by insulin therapy and insulin delivery devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.